BOT 1.59% 32.0¢ botanix pharmaceuticals ltd

It probably could, and that's as an indirect consequence of the...

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,096 Posts.
    lightbulb Created with Sketch. 267
    It probably could, and that's as an indirect consequence of the lack of clinical trials on most cannabinoids - there's a sizeable amount of scientific literature on the substances but only few clinical trials with BOT being apparently the first (and currently only) undertaking trials for dermatological applications.
    And apparently not only the eyebrows of an oncologist could rise, those of an urologist too:
    the latest internationally recognized super-doctor to commit to the medical applications of cannabinoids is none less than the guy who was the lead principal investigator for Viagra and Cialis through the FDA's approved trials: Dr Padma-Nathan.

    https://www.linkedin.com/in/harin-padma-nathan-md-frcs-facs-96b0921/

    There's somebody who certainly knows how to recognize a blockbuster drug (ask Pfizer about it).
    Last edited by aburbe: 09/12/18
 
watchlist Created with Sketch. Add BOT (ASX) to my watchlist
(20min delay)
Last
32.0¢
Change
0.005(1.59%)
Mkt cap ! $707.4M
Open High Low Value Volume
31.5¢ 32.5¢ 31.0¢ $1.169M 3.655M

Buyers (Bids)

No. Vol. Price($)
9 274982 31.5¢
 

Sellers (Offers)

Price($) Vol. No.
32.0¢ 48600 2
View Market Depth
Last trade - 16.10pm 22/11/2024 (20 minute delay) ?
BOT (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.